FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2892300670> ?p ?o ?g. }

• W2892300670 abstract "e18337 Background: Our objectives were to determine advanced imaging use (whole body imaging with bone scan, CT, or PET-CT and breast MRI) during breast cancer surveillance, and to identify drivers of potential imaging overuse as outlined by ASCO’s Choosing Wisely initiative. Methods: Cancer registry records for 2923 women diagnosed with primary breast cancer in Washington State from January 1, 2007 to December 31, 2014 were linked with claims data from two regional commercial insurance plans. Inclusion criteria included women with AJCC stage 0-3 disease treated with curative intent. Women without continuous insurance enrollment from 3 months prior to diagnosis until 14 months after diagnosis were excluded. Surveillance began 4 months after the end of primary therapy and lasted for 15 months or until restart of treatment. Women’s (age, race, family history) and tumor (grade, receptor status, stage) characteristics were collected. Evaluation and management codes from claims data were used to determine mammography, advanced imaging, and tumor biomarker use during the peri-diagnostic and surveillance periods. Multivariate logistic regression models were used to identify factors associated with advanced imaging use during surveillance. Results: Of eligible women, 80.0% (2332/2923) received mammography, 16.5% (483/2932) received whole body imaging, and 21.5% (670/2932) received breast MRI during the surveillance period. Whole body imaging was significantly associated with increasing stage of disease (stage 3: OR = 3.39, 95% CI: 2.30-5.02), peri-diagnostic whole body imaging (OR = 1.80, 95% CI: 1.36-2.38), and surveillance tumor biomarker use (OR = 1.83, 95% CI: 1.46-2.31). Significant predictors of surveillance breast MRI included young age ( < 45 years: OR = 2.40, 95% CI:1.78- 3.25), family history (OR = 1.58, 95% CI:1.26-1.98), peri-diagnostic breast MRI (OR = 2.01, 95% CI: 1.56-2.59), and surveillance tumor biomarker use (OR = 1.74, 95% CI:1.41-2.17). Conclusions: Peri-diagnostic use of advanced imaging and surveillance use of tumor biomarkers are associated with advanced imaging use during surveillance, and may represent targets for interventions to increase adherence to Choosing Wisely clinical guidelines." @default.
• W2892300670 created "2018-09-27" @default.
• W2892300670 creator A5008157537 @default.
• W2892300670 creator A5020615352 @default.
• W2892300670 creator A5024804370 @default.
• W2892300670 creator A5034096046 @default.
• W2892300670 creator A5043530656 @default.
• W2892300670 creator A5046985026 @default.
• W2892300670 creator A5056787074 @default.
• W2892300670 creator A5064006806 @default.
• W2892300670 creator A5073060840 @default.
• W2892300670 date "2017-05-20" @default.
• W2892300670 modified "2023-10-04" @default.
• W2892300670 title "Predictors of advanced imaging use during breast cancer surveillance." @default.
• W2892300670 doi "https://doi.org/10.1200/jco.2017.35.15_suppl.e18337" @default.
• W2892300670 hasPublicationYear "2017" @default.
• W2892300670 type Work @default.
• W2892300670 sameAs 2892300670 @default.
• W2892300670 citedByCount "0" @default.
• W2892300670 crossrefType "journal-article" @default.
• W2892300670 hasAuthorship W2892300670A5008157537 @default.
• W2892300670 hasAuthorship W2892300670A5020615352 @default.
• W2892300670 hasAuthorship W2892300670A5024804370 @default.
• W2892300670 hasAuthorship W2892300670A5034096046 @default.
• W2892300670 hasAuthorship W2892300670A5043530656 @default.
• W2892300670 hasAuthorship W2892300670A5046985026 @default.
• W2892300670 hasAuthorship W2892300670A5056787074 @default.
• W2892300670 hasAuthorship W2892300670A5064006806 @default.
• W2892300670 hasAuthorship W2892300670A5073060840 @default.
• W2892300670 hasConcept C121608353 @default.
• W2892300670 hasConcept C126322002 @default.
• W2892300670 hasConcept C126838900 @default.
• W2892300670 hasConcept C143998085 @default.
• W2892300670 hasConcept C530470458 @default.
• W2892300670 hasConcept C71924100 @default.
• W2892300670 hasConceptScore W2892300670C121608353 @default.
• W2892300670 hasConceptScore W2892300670C126322002 @default.
• W2892300670 hasConceptScore W2892300670C126838900 @default.
• W2892300670 hasConceptScore W2892300670C143998085 @default.
• W2892300670 hasConceptScore W2892300670C530470458 @default.
• W2892300670 hasConceptScore W2892300670C71924100 @default.
• W2892300670 hasLocation W28923006701 @default.
• W2892300670 hasOpenAccess W2892300670 @default.
• W2892300670 hasPrimaryLocation W28923006701 @default.
• W2892300670 hasRelatedWork W1996447975 @default.
• W2892300670 hasRelatedWork W2016750579 @default.
• W2892300670 hasRelatedWork W2128417464 @default.
• W2892300670 hasRelatedWork W2143693583 @default.
• W2892300670 hasRelatedWork W2339726362 @default.
• W2892300670 hasRelatedWork W2370777705 @default.
• W2892300670 hasRelatedWork W2792503157 @default.
• W2892300670 hasRelatedWork W2804238145 @default.
• W2892300670 hasRelatedWork W2909982802 @default.
• W2892300670 hasRelatedWork W2917374116 @default.
• W2892300670 hasRelatedWork W2999628864 @default.
• W2892300670 hasRelatedWork W3000369505 @default.
• W2892300670 hasRelatedWork W3005388795 @default.
• W2892300670 hasRelatedWork W3029350227 @default.
• W2892300670 hasRelatedWork W3030562396 @default.
• W2892300670 hasRelatedWork W3032684392 @default.
• W2892300670 hasRelatedWork W3048742195 @default.
• W2892300670 hasRelatedWork W3148123544 @default.
• W2892300670 hasRelatedWork W3201545357 @default.
• W2892300670 hasRelatedWork W873012390 @default.
• W2892300670 isParatext "false" @default.
• W2892300670 isRetracted "false" @default.
• W2892300670 magId "2892300670" @default.
• W2892300670 workType "article" @default.